Cours de l'action Eli Lilly and Company (LLY)

Eli Lilly and Company is a leading pharmaceutical company engaged in the discovery, development, manufacture, and sale of human pharmaceutical products. It focuses on innovative medicines addressing critical health needs in areas such as diabetes, oncology, immunology, neuroscience, obesity, cardiovascular diseases, cancer, and other therapeutic categories including bone muscle joint disorders, endocrine conditions, dermatology, autoimmune diseases, sleep apnea, migraine, and Alzheimer's disease. The company offers treatments like insulins, GLP-1 therapies for diabetes and obesity, oncology drugs, immunologic agents, and neuroscience products. Eli Lilly and Company supports access initiatives through partnerships for technology transfer and API supply to manufacturers in low- and middle-income countries, enhancing availability of insulins and other therapies in regions like Africa and Bangladesh. It maintains a robust research and development pipeline targeting non-communicable diseases, with late-stage projects in diabetes, cardiovascular, and oncology areas. Founded in 1876 and headquartered in Indianapolis, Indiana, Eli Lilly and Company plays a significant role in the global health technology sector by delivering therapies that improve patient outcomes across diverse medical fields.